Dtsch Med Wochenschr 2013; 138(43): 2201-2206
DOI: 10.1055/s-0033-1349477
Aktuelle Diagnostik & Therapie | Review article
Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Kollagenosen-assoziierte pulmonal-arterielle Hypertonie – Eine Pathologie jenseits der präkapillären Gefäße

Connective tissue disease-related pulmonary arterial hypertension – a pathology beyond the precapillary vessels
S. Günther
1   Medizinische Fakultät der Universität Paris Süd, Le Kremlin-Bicêtre, Frankreich
2   Nationales Referenzzentrum für Pulmonale Hypertonie, Abteilung für Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, Frankreich
3   INSERM U999 „Pulmonal Arterielle Hypertonie: „Pathophysiologie und therapeutische Innovation“, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, Frankreich
,
D. Montani
1   Medizinische Fakultät der Universität Paris Süd, Le Kremlin-Bicêtre, Frankreich
2   Nationales Referenzzentrum für Pulmonale Hypertonie, Abteilung für Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, Frankreich
3   INSERM U999 „Pulmonal Arterielle Hypertonie: „Pathophysiologie und therapeutische Innovation“, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, Frankreich
,
P. Dorfmüller
2   Nationales Referenzzentrum für Pulmonale Hypertonie, Abteilung für Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, Frankreich
3   INSERM U999 „Pulmonal Arterielle Hypertonie: „Pathophysiologie und therapeutische Innovation“, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, Frankreich
4   Abteilung für Pathologie, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, Frankreich
› Author Affiliations
Further Information

Publication History

30 January 2013

20 June 2013

Publication Date:
07 August 2013 (online)

Zusammenfassung

Die pulmonal arterielle Hypertonie (PAH) stellt eine nicht seltene und oft fatale Komplikation von Kollagenosen dar. Veno-okklusive Veränderungen der Lunge werden zunehmend im Rahmen von Kollagenose-assoziierter PAH diagnostiziert. Am häufigsten ist die PVOD in diesem Zusammenhang bei Patienten mit systemischer Sklerose (SSc) beschrieben, auch wenn Fälle im Rahmen von anderen Vertretern dieser Krankheitsgruppe, wie zum Beispiel im Rahmen von Mischkollagenosen oder Lupus Erythematodes, in der Literatur beschrieben werden. Die PVOD ist histologisch durch eine zunehmend progressive Obstruktion von kleinen Pulmonalvenen charakterisiert, die mit zur Erhöhung der pulmonal vaskulären Resistenz beiträgt und im nicht-therapierbaren Rechtsherzversagen endet.

Im klinischen Alltag ist es schwierig, die pulmonale Hypertonie von der PVOD zu unterscheiden. Dennoch sind in den vergangenen Jahren erhebliche Fortschritte in Bezug auf die Diagnostik dieser seltenen Erkrankung erzielt worden. Heute ist es möglich, der Diagnose einer "idiopathischen" PVOD mit nicht invasiven Mitteln nahe zu kommen. Diese Herangehensweise ist bei Kollagenosen erst kürzlich zum ersten Mal beschrieben worden.

Die vorliegende Übersichtsarbeit soll einen aktuellen Überblick über die klinischen, radiologischen und pathologischen Charakteristika der idiopathischen pulmonal veno-okklusiven Erkrankung im Vergleich zu veno-occlusiven Veränderungen im Rahmen von Kollagenosen geben.

Abstract

Pulmonary arterial hypertension (PAH) is a fatal and not uncommon complication in the setting of connective tissue diseases (CTD). Clinical and radiological signs of PVOD are commonly present in systemic slerosis (SSc) and involvement of the post-capillary vasculature is increasingly discussed in other forms of CTD such as Mixed Connective Tissue Disease and Lupus Erythematodes. The histological pattern of pulmonary veno-occlusive disease is frequently observed in CTD-related PAH. PVOD is histologically characterized by an obstruction of small pulmonary veins, which contribute to increasing pulmonary vascular resistance, ultimately leading to right heart failure and death.

In clinical practice, it is difficult to distinguish pulmonary hypertension from PVOD. However, significant progress in the diagnosis of this rare condition has been made in recent years. Today, it is possible to approximate the diagnosis of „idiopathic“ PVOD with non-invasive tools. This approach has recently been described in patients suffering from CTD-related PAH and suspicion of underlying PVOD.

The present review provides an update on clinical, radiological and pathological characteristics of pulmonary veno-occlusive disease in the context of CTD.

 
  • Literatur

  • 1 Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25
  • 2 Brown CH, Harrison CV. Pulmonary veno-occlusive disease. Lancet 1966; 2: 61-65
  • 3 Carreras E et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17: 1713-1720
  • 4 Chawla SK et al. Pulmonary venoocclusive disease. Ann Thorac Surg 1976; 22: 249-253
  • 5 Cox SR et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35: 28-33
  • 6 Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982; 13: 911-915
  • 7 Doll DC, Yarbro JW. Vascular toxicity associated with chemotherapy and hormonotherapy. Curr Opin Oncol 1994; 6: 345-350
  • 8 Dorfmuller P et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38: 893-902
  • 9 Dufour B et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. AJR Am J Roentgenol 1998; 171: 1321-1324
  • 10 Fartoukh M et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161: 216-223
  • 11 Galie N et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263
  • 12 Galie N et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537
  • 13 Günther S et al. Computed tomography findings of pulmonary veno-occlusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012; 9: 2995-3005
  • 14 Hachulla E et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800
  • 15 Hachulla E et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) 2009; 48: 304-308
  • 16 Hamada K et al. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15: 421-423
  • 17 Heath D, Segel N, Bishop J. Pulmonary veno-occlusive disease. Circulation 1966; 34: 242-248
  • 18 Holcomb BW et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118: 1671-1679
  • 19 Höra J. Zur histologie der klinischen "primaren pulmonal-sklerose". Frankf Z Pathol 1934; 47: 100-118
  • 20 Lantuejoul S et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850-857
  • 21 Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973
  • 22 McDonnell PJ, Summer WR, Hutchins GM. Pulmonary veno-occlusive disease. Morphological changes suggesting a viral cause. JAMA 1981; 246: 667-671
  • 23 Montani D et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189-200
  • 24 Montani D et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87: 220-233
  • 25 Nicod P, Moser KM. Primary pulmonary hypertension. The risk and benefit of lung biopsy. Circulation 1989; 80: 1486-1488
  • 26 Nunes H et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74
  • 27 O'Callaghan DS et al. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. Presse Med 2011; 40: e65-e78
  • 28 Overbeek MJ et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-379
  • 29 Rabiller A et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27: 108-113
  • 30 Resten A et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004; 183: 65-70
  • 31 Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117
  • 32 Runo JR et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003; 167: 889-894
  • 33 Saggar R et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36: 893-900
  • 34 Simonneau G et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: 43-54
  • 35 Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944
  • 36 Stovin PG, Mitchinson MJ. Pulmonary hypertension due to obstruction of the intrapulmonary veins. Thorax 1965; 20: 106-113
  • 37 Tamby MC et al. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003; 2: 152-157
  • 38 Tandon BN et al. An epidemic of veno-occlusive disease of liver in central India. Lancet 1976; 2: 271-272
  • 39 Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977; 32: 763-766